DO-BO

What Makes Australia’s HTA Approach to Equity and Health Productivity Unique, Zanfina Ademi?

In this Market Access Podcast episode, Dr. Stefan Walzer sits down with Prof. Zanfania Ademi, a health economist at Monash University, to explore how Australia’s healthcare system is tackling key issues in market access and health technology assessment. Discover how Australia blends international approaches and new methods being developed by Zanfina and her team like distributional cost-effectiveness and productivity-adjusted life years to advance equity and value in healthcare. Tune in for fresh insights on health as an investment, not just a cost,  and what’s next for decision-makers.

Key takeaways from the episode include the shift from qualitative to quantitative measures of equity in HTA, and the use of complex disease models and real-world evidence to drive smarter prevention strategies. The discussion also covers the growing recognition of both paid and unpaid work in productivity metrics, along with lessons from Switzerland on disinvestment, transparency, and the challenges of implementing new value measures in healthcare. Perfect for professionals in market access, health economics, and policy.

Related

By the time most health economists get pulled in, the recipe is already set. In this episode of MAP — the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist […]

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]